Newsletter | March 24, 2020

03.24.20 -- Cynata Therapeutics Tackles FDA's Crackdown On Fraudulent Stem Cell Clinics

 

Greetings Cell & Gene readers,

 

The potential hurt inflicted by the COVID-19 coronavirus on China-based supply-chain confidence will have more biopharma companies reevaluating geographic risks.

 

Fraudulent companies promising false cures for patients are a black eye for the pharmaceutical industry. For that reason, many companies are applauding the FDA’s recent crackdown on stem cell clinics that tout treatments with no data to back up their claims. One of those companies is Cynata Therapeutics.

 

Erin Harris, editor in chief
Follow me on Twitter

Industry Insights
Developing A Scalable Process For Adenovirus Manufacturing
White Paper | By Mats Lundgren, GE Healthcare Life Sciences

To address the growing need for speed and efficiency in viral vector manufacturing, GE developed a process for adenovirus manufacturing that not only meets regulatory requirements but is also scalable.

REMS Technology Of Today And Tomorrow: Transformative Solutions To Help Reduce Burden And Improve Safety
Article | By Natalie O’Donnell and Justin Wilson, United BioSource LLC (UBC)

During the 12th annual REMS Summit in Virginia, UBC’s Natalie O’Donnell, corporate vice president, safety, REMS, and strategic engagement, and Justin Wilson, director, software development and technology, presented a session on the impact technology has had on REMS and the potential effect it can have in the future.

A Primer On Cancer Immunotherapy
Article | Premier Research

Widespread use of immune checkpoint therapy to treat cancers is hampered by unpredictable response rates and immune-related adverse events. To address these challenges, combination therapies are increasingly being studied as a strategy for improving response and overcoming resistance. 

Implications Of Inaccurate Forecasting On Biologics Manufacturing
Article | Thermo Fisher Scientific

Inaccurate demand forecasts can have significant implications for companies developing biologics. And, it is increasingly difficult to locate capacity to respond to demand changes.

Process Development For Cell Therapy And Viral Gene Therapy
Webinar | MilliporeSigma Cell and Gene

Process development is a critical enabler to bring safe, effective, sustainable products to market to address patient needs. In this webinar we will discuss our strategies for developing lentivirus and adeno associated virus (AAV) and the impact these early decisions can have on commercial readiness.

Solutions
Bio-Rad ZE5 Cell Analyzer
Bio-Rad Laboratories, Inc.
DrumQuik PRO Series: Drum Connectors
CPC
Connect With Cell & Gene:
      Twitter